US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Metsera (MTSR US), a biotech using peptides to treat obesity, overweight and related conditions opened 41.7% above the issue price. </li>
<li>The company was seeking a specific cash-raise of $275 million and was not looking to allow further dilution.</li>
<li>IPOs in the biotech sector are a "sell-the-news" event until we see on the tape otherwise.</li>
</ul>


Metsera (MTSR US), a biotech using peptides to treat obesity, overweight and related conditions opened 41.7% above the issue price. 
The company was seeking a specific cash-raise of $275 million and was not looking to allow further dilution.
IPOs in the biotech sector are a "sell-the-news" event until we see on the tape otherwise.


Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

<ul>
<li>The GLP-1 market has experienced a recent boom and Metsera is capitalizing on this with a well-times IPO.</li>
<li>According to our sources, the deal is well-oversubscribed with the books closing Wednesday at 4pm for a Friday debut.</li>
<li>The company is seeking a mega valuation of$1.8b if priced at the high-end of the range. An IPO valuation at these levels would put the company in "rare-company".</li>
</ul>


The GLP-1 market has experienced a recent boom and Metsera is capitalizing on this with a well-times IPO.
According to our sources, the deal is well-oversubscribed with the books closing Wednesday at 4pm for a Friday debut.
The company is seeking a mega valuation of$1.8b if priced at the high-end of the range. An IPO valuation at these levels would put the company in "rare-company".


Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut

<ul>
<li>Metsera, Inc. is developing next-generation injectable and oral NuSH analog peptides for obesity treatment.</li>
<li>ARCH Venture Partners, Google Ventures and Softbank's Vision Fund are all existing investors in this IPO.</li>
<li>The company is seeking an IPO valuation nearing $2bn for the company with a Phase III product candidate.</li>
</ul>


Metsera, Inc. is developing next-generation injectable and oral NuSH analog peptides for obesity treatment.
ARCH Venture Partners, Google Ventures and Softbank's Vision Fund are all existing investors in this IPO.
The company is seeking an IPO valuation nearing $2bn for the company with a Phase III product candidate.


Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation

<ul>
<li>Biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions filed for Q1 IPO</li>
<li>Preliminary Phase 2 results in January suggested a durable pharmacodynamic, or PD, effect consistent with the observed half-life.</li>
<li>ARCH Ventures along with Fidelity are among the existing shareholders as this company enters begins its road to be a publicly traded company</li>
</ul>


Biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions filed for Q1 IPO
Preliminary Phase 2 results in January suggested a durable pharmacodynamic, or PD, effect consistent with the observed half-life.
ARCH Ventures along with Fidelity are among the existing shareholders as this company enters begins its road to be a publicly traded company


Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>In a week of bad industry news, biopharma surprisingly held onto its bounce from recent two-year lows.</li><li>With pharma tariffs now expected by June and federal health agencies’ prospects looking worse, we may be close to peak negativity, but too much uncertainty remains for any confidence in a bottom.</li><li>In obesity, LLY had a win for an oral GLP-1, while PFE lost, affecting NVO, GPCR, VKTX, AMGN, MTSR, ALT, and TERN. VERV gained on CVD data and BMY’s heart drug failed, affecting CYTK and EWTX, while MURA stopped development.</li></ul>

In a week of bad industry news, biopharma surprisingly held onto its bounce from recent two-year lows.With pharma tariffs now expected by June and federal health agencies’ prospects looking worse, we may be close to peak negativity, but too much uncertainty remains for any confidence in a bottom.In obesity, LLY had a win for an oral GLP-1, while PFE lost, affecting NVO, GPCR, VKTX, AMGN, MTSR, ALT, and TERN. VERV gained on CVD data and BMY’s heart drug failed, affecting CYTK and EWTX, while MURA stopped development.

Biopharma Week in Review Shrugging Off Constant Bad News; LLY Winning Obesity Drug Race

United States

Clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Metsera (MTSR US)

Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

Metsera, a biotech using peptides for obesity, opened 41.7% above issue price in IPO, seeking $275 million without further dilution. Biotech IPOs...

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut

Metsera is set to capitalize on the booming GLP-1 market with a well-timed IPO seeking a mega valuation of $1.8b, putting them in "rare company".

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation

Metsera, Inc. is developing innovative obesity treatments with backing from top investors, aiming for a $2bn IPO valuation.

IPO Boutique

Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

Biotech company developing NuSH peptides for obesity files for Q1 IPO with promising Phase 2 results and support from ARCH Ventures and Fidelity.

IPO Boutique

Biopharma Week in Review Shrugging Off Constant Bad News; LLY Winning Obesity Drug Race

With pharma tariffs now expected by June and federal health agencies’ prospects looking worse, we may be close to peak negativity, but too much...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

​Metsera, a biotech using peptides for obesity, opened 41.7% above issue price in IPO, seeking $275 million without further dilution. Biotech IPOs...

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut

​Metsera is set to capitalize on the booming GLP-1 market with a well-timed IPO seeking a mega valuation of $1.8b, putting them in "rare company".

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation

​Metsera, Inc. is developing innovative obesity treatments with backing from top investors, aiming for a $2bn IPO valuation.

IPO Boutique

Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

​Biotech company developing NuSH peptides for obesity files for Q1 IPO with promising Phase 2 results and support from ARCH Ventures and Fidelity.

IPO Boutique

Biopharma Week in Review Shrugging Off Constant Bad News; LLY Winning Obesity Drug Race

With pharma tariffs now expected by June and federal health agencies’ prospects looking worse, we may be close to peak negativity, but too much...

Water Tower Research

Metsera, a biotech using peptides for obesity, opened 41.7% above issue price in IPO, seeking $275 million without further dilution. Biotech IPOs...

Metsera is set to capitalize on the booming GLP-1 market with a well-timed IPO seeking a mega valuation of $1.8b, putting them in "rare company".

Metsera, Inc. is developing innovative obesity treatments with backing from top investors, aiming for a $2bn IPO valuation.

Biotech company developing NuSH peptides for obesity files for Q1 IPO with promising Phase 2 results and support from ARCH Ventures and Fidelity.